Detailed Information

Cited 0 time in webofscience Cited 66 time in scopus
Metadata Downloads

A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunctionopen access

Authors
Cha R.-H.Kang S.W.Park C.W.Cha D.R.Na K.Y.Kim S.G.Yoon S.A.Han S.Y.Chang J.H.Park S.K.Lim C.S.Kim Y.S.
Issue Date
2016
Publisher
American Society of Nephrology
Citation
Clinical Journal of the American Society of Nephrology, v.11, no.4, pp 559 - 567
Pages
9
Indexed
SCIE
SCOPUS
Journal Title
Clinical Journal of the American Society of Nephrology
Volume
11
Number
4
Start Page
559
End Page
567
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7114
DOI
10.2215/CJN.12011214
ISSN
1555-9041
1555-905X
Abstract
Background and objectives The notion that oral intestinal sorbent AST-120 slows renal disease progression has not been evaluated thoroughly. In this study, we investigated the long-term effect of AST-120 on renal disease progression (doubling of serum creatinine, eGFR decrease >50%, or initiation of RRT) in patients with advanced CKD. Design, setting, participants, & measurements We prospectively recruited 579 patients (CKD stage 3 or 4) from 11 medical centers in Korea from March 4, 2009 to August 31, 2010 and randomized them into an AST-120 arm and a control arm. Patients in the AST-120 arm were given 6 g AST-120 in three divided doses per day, and those in the control arm received only standard conventional treatment (open-label design) for 36 months or until the occurrence of primary outcomes. Results Levels of serum and urine indoxyl sulfate and β2-microglobulin decreased throughout the study period in both treatment arms; however, there was not a significant difference in change in uremic toxins in the AST-120 and control arms. The two arms were not different in the occurrence of composite primary outcomes (100 events in 272 individuals in the AST-120 arm and 100 events in 266 individuals in the control arm; hazard ratio, 1.12; 95% confidence interval, 0.85 to 1.48; log-rank P=0.45). The decline in eGFR and change in proteinuria were similar in the two treatment arms over time (Prandomization–time =0.64 and Prandomization–time =0.16, respectively). There was no difference in mortality (nine deaths in the AST-120 arm and 11 deaths in the control arm; log-rank P=0.73) or unplanned hospitalizations (102 in the AST-120 arm and 109 in the control arm; log-rank P=0.76) in the two treatment arms. There was no significant difference of the health–related quality of life score between the two arms. Conclusions Long-term use of AST-120 added to standard treatment did not change renal disease progression, proteinuria, mortality, and health–related quality of life in patients with advanced renal dysfunction. © 2016 by the American Society of Nephrology.
Files in This Item
Appears in
Collections
2. Clinical Science > Department of Nephrology and Hypertension > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Cha, Dae Ryong photo

Cha, Dae Ryong
Ansan Hospital (Department of Nephrology and Hypertension, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE